← ACTU
ACTU— ACTUATE THERAPEUTICS, INC.
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Research and development | $10.3M-44.9% | $18.7M-14.0% | $21.7M |
| General and administrative | $12.2M+88.2% | $6.5M+98.6% | $3.3M |
| Total operating expenses | $22.5M-10.6% | $25.2M+0.7% | $25.0M |
| Loss from operations | -$22.5M+10.6% | -$25.2M-0.7% | -$25.0M |
| Change in estimated fair value of warrant liability | $0+100.0% | -$79K+1.2% | -$80K |
| Gain on settlement of warrants | $0-100.0% | $343K | $0 |
| Loss on issuance of related party convertible notes payable at fair value | $0+100.0% | -$400K | $0 |
| Change in estimated fair value of related party convertible notes payable | $0+100.0% | -$2.2M | $0 |
| Interest expense | -$20K-8.2% | -$19K+57.1% | -$44K |
| Interest income | $288K+29.4% | $222K-37.0% | $353K |
| Total other income (expense), net | $267K+112.6% | -$2.1M-1026.9% | $229K |
| Net loss | -$22.2M+18.5% | -$27.3M-10.3% | -$24.7M |
| Weighted-average shares of common stock outstanding, basic | $21.0M+151.1% | $8.4M+483.5% | $1.4M |
| Weighted-average shares of common stock outstanding, diluted | $21.0M+151.1% | $8.4M+483.5% | $1.4M |
| Net loss per share attributable to common stockholders, basic | -$1.06+67.5% | -$3.26+81.1% | -$17.24 |
| Net loss per share attributable to common stockholders, diluted | -$1.06+67.5% | -$3.26+81.1% | -$17.24 |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.